These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15812509)

  • 1. Can the Institute of Medicine review the FDA?
    Carroll BJ
    Nat Med; 2005 Apr; 11(4):369. PubMed ID: 15812509
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to "Can the Institute of Medicine review the FDA?".
    Fineberg HV
    Nat Med; 2005 Jun; 11(6):589. PubMed ID: 15937463
    [No Abstract]   [Full Text] [Related]  

  • 3. The Institute of Medicine report on the FDA: where is the science?
    Philipson T; Jena AB; Sun E
    Health Econ; 2007 Mar; 16(3):219-21. PubMed ID: 17315264
    [No Abstract]   [Full Text] [Related]  

  • 4. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.
    Tilson HH; Madre LK; Califf RM
    Clin Pharmacol Ther; 2007 Aug; 82(2):118-21. PubMed ID: 17632533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conflicts of interest in medical education: recommendations from the Pew task force on medical conflicts of interest.
    Korn D; Carlat D
    JAMA; 2013 Dec; 310(22):2397-8. PubMed ID: 24327035
    [No Abstract]   [Full Text] [Related]  

  • 7. IOM: congress must reform FDA to improve drug safety.
    Young D
    Am J Health Syst Pharm; 2006 Nov; 63(21):2032, 2034. PubMed ID: 17057032
    [No Abstract]   [Full Text] [Related]  

  • 8. US body demands tougher global response to "bad drugs".
    Roehr B
    BMJ; 2013 Feb; 346():f1115. PubMed ID: 23423506
    [No Abstract]   [Full Text] [Related]  

  • 9. Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.
    Crawford LM
    Food Drug Law J; 2005; 60(2):99-102. PubMed ID: 16097087
    [No Abstract]   [Full Text] [Related]  

  • 10. The report of the Institute of Medicine on drug safety.
    Somberg J
    Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of the FDA backgrounder on platinum in silicone breast implants: implications for public health policy.
    Maharaj SV
    Int J Health Serv; 2008; 38(1):95-102. PubMed ID: 18341124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The National Academy of Medicine's Vision: Leadership, Innovation, and Impact for a Healthier Future.
    Dzau VJ
    JAMA; 2015 Nov; 314(20):2127-8. PubMed ID: 26540559
    [No Abstract]   [Full Text] [Related]  

  • 13. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety.
    Lo Re V; Strom BL
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):818-25. PubMed ID: 17436357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IOM-CAM roller coaster.
    Hammerly M
    Altern Ther Health Med; 2003; 9(4):16. PubMed ID: 12868247
    [No Abstract]   [Full Text] [Related]  

  • 16. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
    Psaty BM; Burke SP
    N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
    [No Abstract]   [Full Text] [Related]  

  • 17. The National Academy of Sciences/Institute of Medicine.
    Keramidas SL
    J Am Coll Dent; 1995; 62(1):32-3. PubMed ID: 7730518
    [No Abstract]   [Full Text] [Related]  

  • 18. Blueprint for a stronger Food and Drug Administration.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2006 Oct; 355(17):1821. PubMed ID: 17030844
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA responds to institute of medicine drug safety recommendations--in part.
    Psaty BM; Charo RA
    JAMA; 2007 May; 297(17):1917-20. PubMed ID: 17473302
    [No Abstract]   [Full Text] [Related]  

  • 20. The future of drug safety.
    Breckenridge A
    Clin Pharmacol Ther; 2007 Feb; 81(2):161-3. PubMed ID: 17259942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.